Tranilast is known as a drug that inhibits the release of TGF-β from keloid fibroblasts, as well as the release of inflammatory cytokines such as TGF-β1, IL-1β from monocytes and macrophages [54]. The gene discussed is TGFB1; the disease is keloid.